Literature DB >> 30598495

Lenalidomide can be safely combined with chlorambucil and rituximab in older patients with chronic lymphocytic leukemia.

Candida Vitale1, Alessandra Ferrajoli2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30598495      PMCID： PMC6312007          DOI： 10.3324/haematol.2018.206359

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  19 in total

1.  Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.

Authors:  Christine I Chen; P Leif Bergsagel; Harminder Paul; Wei Xu; Anthea Lau; Nimisha Dave; Vishal Kukreti; Ellen Wei; Chungyee Leung-Hagesteijn; Zhi Hua Li; Joseph Brandwein; Mariela Pantoja; James Johnston; Spencer Gibson; Tiffany Hernandez; David Spaner; Suzanne Trudel
Journal:  J Clin Oncol       Date:  2010-12-28       Impact factor: 44.544

2.  Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma.

Authors:  Chan Yoon Cheah; Loretta J Nastoupil; Sattva S Neelapu; Sheryl G Forbes; Yasuhiro Oki; Nathan H Fowler
Journal:  Blood       Date:  2015-05-21       Impact factor: 22.113

3.  Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium.

Authors:  Danelle F James; Lillian Werner; Jennifer R Brown; William G Wierda; Jacqueline C Barrientos; Januario E Castro; Andrew Greaves; Amy J Johnson; Laura Z Rassenti; Kanti R Rai; Donna Neuberg; Thomas J Kipps
Journal:  J Clin Oncol       Date:  2014-05-27       Impact factor: 44.544

4.  Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia.

Authors:  Anthony R Mato; Kenneth A Foon; Tatyana Feldman; Stephen J Schuster; Jakub Svoboda; Kar Fai Chow; Marisa Valentinetti; Mary Mrkulic; Kelly Azzollini; Gabriella Gadaleta; Pritish K Bhattacharyya; Joshua Zenreich; Lauren-Nicole Pascual; Kara Yannotti; Sabrina Kdiry; Christina Howlett; Lauren Strelec; David Porter; Coleen Bejot; André Goy
Journal:  Am J Hematol       Date:  2015-03-30       Impact factor: 10.047

5.  Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.

Authors:  Leslie A Andritsos; Amy J Johnson; Gerard Lozanski; William Blum; Cheryl Kefauver; Farrukh Awan; Lisa L Smith; Rosa Lapalombella; Sarah E May; Chelsey A Raymond; Da-Sheng Wang; Robert D Knight; Amy S Ruppert; Amy Lehman; David Jarjoura; Ching-Shih Chen; John C Byrd
Journal:  J Clin Oncol       Date:  2008-04-21       Impact factor: 44.544

6.  A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL.

Authors:  Chaitra Ujjani; Hongkun Wang; Alan Skarbnik; Neel Trivedi; Pari Ramzi; Nadia Khan; Bruce D Cheson
Journal:  Blood Adv       Date:  2018-04-10

7.  Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.

Authors:  Joseph A Fraietta; Kyle A Beckwith; Prachi R Patel; Marco Ruella; Zhaohui Zheng; David M Barrett; Simon F Lacey; Jan Joseph Melenhorst; Shannon E McGettigan; Danielle R Cook; Changfeng Zhang; Jun Xu; Priscilla Do; Jessica Hulitt; Sagar B Kudchodkar; Alexandria P Cogdill; Saar Gill; David L Porter; Jennifer A Woyach; Meixiao Long; Amy J Johnson; Kami Maddocks; Natarajan Muthusamy; Bruce L Levine; Carl H June; John C Byrd; Marcela V Maus
Journal:  Blood       Date:  2016-01-26       Impact factor: 22.113

8.  Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.

Authors:  Simon F Lacey; Elena J Orlando; Joseph A Fraietta; Iulian Pruteanu-Malinici; Mercy Gohil; Stefan Lundh; Alina C Boesteanu; Yan Wang; Roddy S O'Connor; Wei-Ting Hwang; Edward Pequignot; David E Ambrose; Changfeng Zhang; Nicholas Wilcox; Felipe Bedoya; Corin Dorfmeier; Fang Chen; Lifeng Tian; Harit Parakandi; Minnal Gupta; Regina M Young; F Brad Johnson; Irina Kulikovskaya; Li Liu; Jun Xu; Sadik H Kassim; Megan M Davis; Bruce L Levine; Noelle V Frey; Donald L Siegel; Alexander C Huang; E John Wherry; Hans Bitter; Jennifer L Brogdon; David L Porter; Carl H June; J Joseph Melenhorst
Journal:  Nat Med       Date:  2018-04-30       Impact factor: 53.440

9.  Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.

Authors:  Paul M Barr; Tadeusz Robak; Carolyn Owen; Alessandra Tedeschi; Osnat Bairey; Nancy L Bartlett; Jan A Burger; Peter Hillmen; Steven Coutre; Stephen Devereux; Sebastian Grosicki; Helen McCarthy; Jianyong Li; David Simpson; Fritz Offner; Carol Moreno; Cathy Zhou; Lori Styles; Danelle James; Thomas J Kipps; Paolo Ghia
Journal:  Haematologica       Date:  2018-06-07       Impact factor: 9.941

10.  Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia.

Authors:  Arnon P Kater; Marinus H J van Oers; Yvette van Norden; Lina van der Straten; Julia Driessen; Ward F M Posthuma; Martin Schipperus; Martine E D Chamuleau; Marcel Nijland; Jeanette K Doorduijn; Michel Van Gelder; Mels Hoogendoorn; Francien De Croon; Shulamiet Wittebol; J Martijn Kerst; Erik W A Marijt; Reinier A P Raymakers; Martijn R Schaafsma; Johan A Dobber; Sabina Kersting; Mark-David Levin
Journal:  Haematologica       Date:  2018-08-16       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.